NHC 100: SUPPLY CHAIN (HEALTH COMMODITIES) MANAGEMENT PRECEPTORSHIP
Improving Access and reliable supply to quality cancer (and NCD) medicines and commodities in sub-Saharan Africa
August 4th 2020 – September 24th 2020
THIS EDUCATIONAL ACTIVITY IS BROUGHT TO YOU BY INTERNATIONAL CANCER INSTITUTE (ICI) IN PARTNERSHIP WITH MEDS HEALTH SUPPLY CHAIN & COMMODITY MANAGEMENT TRAINING PROGRAM
Lead Faculty: Agnes Njue
Capacity Building Manager-Mission for Essential Drugs and Supplies (MEDS)
P.O. Box 78040 –00507, Viwandani- Nairobi, KENYA
Co-Lead Faculty: Dr. Collins Saina, PharmD
Oncology Pharmacist-Office of Clinical Care
International Cancer Institute (ICI)
P.O. Box 8088-30100 Eldoret, Kenya
Course Director: Fredrick Chite Asirwa MD
Consultant Physician. Medical Oncologist & Hematologist
Executive Director/CEO: International Cancer Institute (ICI)
P.O. Box 8088, Code 30100 Eldoret, Kenya
This activity is supported by educational grant from Roche as part of the ICI_Roche Shining Tower Project (STP) and Takeda as part of Blueprint for innovative Access Program.
Accreditation is by KMPDC, KPPB, COC and NCK
ICI Education & Training Mission Statement
The ICI Preceptorship Program Mission is to measurably contribute to cancer patients’ safety and health outcomes and to support practice improvement by providing CME/CPD activities that enhance the ability of physicians and other health-care team members to deliver quality and optimal healthcare services.
The purpose of ICI Preceptorship Program is to develop educational activities that clearly link the needs of the learner/participants with the planning process, format and delivery of each activity, resulting in high-quality continuing medical education/continued Professional Development opportunities that will increase the knowledge, competence and performance of health-care providers.
The ICI Preceptorship Program activities include practical, evidence-based, best clinical practice information for a broad variety of common oncology and hematology conditions, innovations in primary and specialty patient care in NCDs, new procedural training and specialty fora. Appropriate content for each course is determined based on the results of a practice gap analysis relative to the target audience’s scope of practice, as well as the identified expected outcomes. Content is free of commercial bias. General Target Audience: ICI Preceptorship/CME/CPD activities focus on the needs of generalist, Primary Care Providers, Pharmacists and specialist physicians and other multidisciplinary health-care team members at ICI affiliated cancer centers nationally and in sub-Saharan Africa as appropriate.
Type of Activities Provided by ICI
In order to accomplish our educational goals, ICI CME uses a range of activity formats based on the content and desired results of the activity. Current offerings include live and video conferenced activities, live regularly scheduled series, internet CME activities, enduring materials and hands-on skills workshops. ICI also jointly sponsors activities with regional specialty societies, non-profit educational organizations and government agencies when mutually desired goals and outcomes are best achieved by such relationships.
The primary target audience for this course (NHC 100) comprise health care professionals (primary care physicians, physicians-in-training, Pharmacists, Pharmaceutical Technicians, oncology nurses, nurse practitioners, and physician assistants) involved and/or interested in supply chain and health commodities management for Cancer and NCD drugs and commodities.
At the end of this course, participants will be able to:
- To understand the role of Health Care Professionals (HCPs) in management of health commodities
- To identify good practice in inventory management of health commodities
- To outline key principles in Rational Medicine Use of Health Commodities
- To understand the role of Health Care Providers in Pharmacovigilance
- To explore potential research areas within the supply chain management
Disclosure of Conflicts of Interest
International Cancer Institute (ICI) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by ICI for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The faculty must report any financial relationships or contractual relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA or KPPB. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Method of Participation and Request for Credit
To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately.
NHC 100 COURSE OUTLINE
Participants should be willing to spend at least 4 hours per week (comprising of 2 online virtual classes/ week and assignments, homework, projects, etc) on this course over a period of 8 weeks. (Duration 32 hours)
This activity is supported by an educational grant from Roche as part of the ICI_Roche Shining Tower Project (STP) and Takeda as part of Blueprint for the innovative Access Program.